Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
General Internal Medicine
•
Inflammatory Bowel Disease
•
Gastroenterology
•
Pulmonology
•
Diffuse Parenchymal Lung Disease
What is your approach to managing ILD associated with inflammatory bowel disease?
Related Questions
Do you ever consider close clinical monitoring over antifibrotic therapy in patients ascribed an MDD diagnosis of IPF who have normal lung function and are asymptomatic?
What criteria do you use to decide when to perform a BAL in hypersensitivity pneumonitis?
In a patient with low titer +anti-SAE antibody and known ILD, but no other clinical features of dermatomyositis, how would you approach further testing or would you treat the patient as dermatomyositis associated ILD?
How do you approach the treatment of Crohn's colitis in the setting of immunosuppression for liver transplant?
How do you approach a patient with sarcoidosis who cannot tolerate steroids and who is developing ILD?
Would you consider adding or switching to pirfenidone for a patient with progressing UIP (based on imaging and PFTs) who is currently on nintedanib?
How would you manage a patient with Crohn's disease on a biologic and presents with non-bloody diarrhea, normal-appearing mucosa on sigmoidoscopy but severe colitis on biopsy with a positive CMV stain?
How do you approach management of ILD in the presence of weakly positive RF and ANA but no other objective systemic findings of connective tissue disease?
How long after initiating mycophenolate do you wait before tapering prednisone off in patients with myositis-associated ILD?
When and how should we use biomarkers (i.e., CRP, stool calprotectin, mAb levels) to guide or optimize medical management of Crohn’s disease or ulcerative colitis?
